Analysis of the immune checkpoint V-domain Ig-containing suppressor of T-cell activation (VISTA) in endometrial cancer

Liju Zong, Shengwei Mo, Zezheng Sun, Zhaohui Lu, Shuangni Yu, Jie Chen, Yang Xiang, Liju Zong, Shengwei Mo, Zezheng Sun, Zhaohui Lu, Shuangni Yu, Jie Chen, Yang Xiang

Abstract

V-domain Ig-containing suppressor of T-cell activation (VISTA) is a novel immune checkpoint protein and a potential immunotherapeutic target. However, its expression in endometrial cancer has not been clearly defined. This study aimed to investigate VISTA expression and determine its associations with clinicopathological features, molecular subtypes, programmed cell death-ligand 1 (PD-L1) expression, CD8+ T-cell count, and survival in a cohort of 839 patients with endometrial cancer. Using direct sequencing of the polymerase epsilon (POLE) exonuclease domain and immunohistochemistry for mismatch repair (MMR) proteins and p53, we stratified endometrial cancers into four molecular subtypes: POLE ultramutated, MMR-deficient, p53-mutant, and nonspecific molecular profile (NSMP). PD-L1, CD8, and VISTA were detected via immunohistochemistry. VISTA was expressed in the immune cells of 76.6% (643/839) of the samples and in the tumor cells of 6.8% (57/839). VISTA positivity in the immune cells was frequent in tumors staged I-III, those with positive PD-L1 or high CD8+ T-cell density, and those representing POLE ultramutated and MMR-deficient subtypes. Furthermore, VISTA positivity in tumor cells was more frequent in clear cell carcinoma samples. VISTA in immune cells was associated with improved survival in the entire cohort as well as in the endometrioid histology, stage I, PD-L1-negative, MMR-deficient, MMR-proficient, and high and low number of CD8+ T-cell-infiltrated tumor subgroups. VISTA in immune cells was a prognostic factor overall, as well as in patients with endometrioid histology, independent of molecular subtype or CD8+ T-cell density. The data produced by this study, which was the largest to focus on VISTA expression in patients with endometrial cancer to date, suggest that VISTA is a predictor of improved survival.

Trial registration: ClinicalTrials.gov NCT04475523 NCT02812875.

© 2021. The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.

References

    1. Morice, P., Leary, A., Creutzberg, C., Abu-Rustum, N. & Darai, E. Endometrial cancer. Lancet 387, 1094–1108 (2016).
    1. Wang, L. et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J. Exp. Med. 208, 577–592 (2011).
    1. Flies, D. B. et al. Coinhibitory receptor PD-1H preferentially suppresses CD4(+) T cell-mediated immunity. J. Clin. Invest. 124, 1966–1975 (2014).
    1. Wang, J. et al. VSIG-3 as a ligand of VISTA inhibits human T-cell function. Immunology 156, 74–85 (2019).
    1. Johnston, R. J. et al. VISTA is an acidic pH-selective ligand for PSGL-1. Nature 574, 565–570 (2019).
    1. Liu, J. et al. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc. Natl Acad. Sci. USA 112, 6682–6687 (2015).
    1. ElTanbouly, M. A., Schaafsma, E., Noelle, R. J. & Lines, J. L. VISTA: coming of age as a multi-lineage immune checkpoint. Clin. Exp. Immunol. 200, 120–130 (2020).
    1. Wu, L. et al. Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma. Cancer Immunol. Immunother. 66, 627–636 (2017).
    1. Wang, Y. et al. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and VISTA in craniopharyngioma. J. Immunother. Cancer 8, e000406 (2020)
    1. Zong, L. et al. High VISTA expression correlates with a favorable prognosis in patients with colorectal cancer. J. Immunother. 44, 22–28 (2021).
    1. Zong, L., Zhou, Y., Zhang, M., Chen, J. & Xiang, Y. VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer. Cancer Immunol. Immunother. 69, 33–42 (2020).
    1. Zong, L. et al. Expression of the immune checkpoint VISTA in breast cancer. Cancer Immunol. Immunother. 69, 1437–1446 (2020).
    1. Zhang, M. et al. VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma. BMC Cancer 18, 511 (2018).
    1. Muller, S. et al. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma. Mod. Pathol. 33, 303–311 (2020).
    1. Loeser, H. et al. The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma. Oncoimmunology 8, e1581546 (2019).
    1. Villarroel-Espindola, F. et al. Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human non-small cell lung cancer. Clin. Cancer Res. 24, 1562–1573 (2018).
    1. Cancer Genome Atlas Research Network et al. Integrated genomic characterization of endometrial carcinoma. Nature 497, 67–73 (2013).
    1. Mulati, K. et al. VISTA expressed in tumour cells regulates T cell function. Br. J. Cancer 120, 115–127 (2019).
    1. Yu, S. et al. Detection of POLE subtypes in high-grade endometrioid carcinoma by BaseScope-ISH assay. Front. Oncol. 9, 831 (2019).
    1. Zong, L. et al. B7-H3 and VISTA are highly expressed in gestational trophoblastic neoplasia. Histopathology 75, 421–430 (2019).
    1. Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676–682 (2012).
    1. Bosse, T. et al. Molecular classification of grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups. Am. J. Surg. Pathol. 42, 561–568 (2018).
    1. Vermij, L., Smit, V., Nout, R. & Bosse, T. Incorporation of molecular characteristics into endometrial cancer management. Histopathology 76, 52–63 (2020).
    1. Kuklinski, L. F. et al. VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival. Cancer Immunol. Immunother. 67, 1113–1121 (2018).
    1. Boger, C., Behrens, H. M., Kruger, S. & Rocken, C. The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: a future perspective for a combined gastric cancer therapy? Oncoimmunology 6, e1293215 (2017).
    1. Gao, J. et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat. Med. 23, 551–555 (2017).
    1. Blando, J. et al. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc. Natl Acad. Sci. USA 116, 1692–1697 (2019).
    1. Zong, L. et al. Expression and significance of immune checkpoints in clear cell carcinoma of the uterine cervix. J. Immunol. Res. 2020, 1283632 (2020).
    1. Howitt, B. E. et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 1, 1319–1323 (2015).
    1. Talhouk, A. et al. Molecular subtype not immune response drives outcomes in endometrial carcinoma. Clin. Cancer Res. 25, 2537–2548 (2019).
    1. Yum, J. I. & Hong, Y. K. Terminating cancer by blocking VISTA as a novel immunotherapy: hasta la vista, baby. Front. Oncol. 11, 658488 (2021).
    1. Concin, N. et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int. J. Gynecol. Cancer 31, 12–39 (2021).
    1. Pagès, F. et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 391, 2128–2139 (2018).
    1. Xie, S. et al. Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors. Cancer Immunol. Immunother. 67, 1685–1694 (2018).
    1. Le Mercier, I. et al. VISTA regulates the development of protective antitumor immunity. Cancer Res. 74, 1933–1944 (2014).
    1. Lines, J. L. et al. VISTA is an immune checkpoint molecule for human T cells. Cancer Res. 74, 1924–1932 (2014).
    1. Edwards, J. et al. Prevalence and cellular distribution of novel immune checkpoint targets across longitudinal specimens in treatment-naive melanoma patients: implications for clinical trials. Clin. Cancer Res. 25, 3247–3258 (2019).

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa